ACADIA Pharmaceuticals (NASDAQ:ACAD) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

ACADIA Pharmaceuticals (NASDAQ:ACAD) announced its earnings results on Wednesday. The biopharmaceutical company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.11, FiscalAI reports. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. The business had revenue of $342.30 million during the quarter, compared to the consensus estimate of $332.58 million. During the same quarter in the prior year, the firm earned $0.42 earnings per share. The business’s quarterly revenue was up 22.8% compared to the same quarter last year.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

• ACADIA reported $342 million in Q3 revenue, up 22% year over year on an adjusted basis. DAYBUE sales reached a record $140 million, up 39%, while NUPLAZID generated $202 million, up 12%; growth for both brands was largely volume-driven.
• ACADIA raised its 2026 DAYBUE sales guidance to $505 million–$520 million, citing STIX momentum, with more than half of U.S. patients using the formulation by quarter-end. The company also highlighted its Germany launch and a newly allowed U.S. patent expected to protect both formulations through March 2041, while reiterating its $700 million sales ambition for 2028.
• NUPLAZID guidance was narrowed to $760 million–$775 million, with management citing the time needed for its expanded sales force to build prescribing relationships. ACADIA maintained its ambition of approximately $1 billion in NUPLAZID sales by the end of 2028.
• The phase II RADIANT trial of remlifanserin in Alzheimer’s disease psychosis narrowly missed statistical significance on its primary endpoint (p=0.0603), although the 60 mg dose showed activity across four efficacy scales and a nominally significant result on a key secondary endpoint. ACADIA plans to advance the 60 mg dose and adjust trial conduct and statistical methods for phase III; the primary endpoint remains unchanged.
• ACADIA expects phase II results for remlifanserin in Lewy body dementia psychosis and for ACP-211 in major depressive disorder in the second half of 2027, extending the timeline for pipeline updates. The company ended the quarter with $976 million in cash.

ACADIA Pharmaceuticals Stock Up 4.4%

Shares of ACAD traded up $0.90 on Wednesday, reaching $21.47. The stock had a trading volume of 4,719,887 shares, compared to its average volume of 1,533,597. The firm has a market capitalization of $3.70 billion, a PE ratio of 9.67 and a beta of 0.87. The firm has a 50-day moving average of $23.20 and a 200 day moving average of $23.64. ACADIA Pharmaceuticals has a twelve month low of $18.39 and a twelve month high of $30.96.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Mark Schneyer sold 3,321 shares of ACADIA Pharmaceuticals stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the completion of the transaction, the executive vice president owned 71,322 shares in the company, valued at approximately $1,489,203.36. The trade was a 4.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 26.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $35.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, October 19th. Royal Bank Of Canada decreased their price objective on ACADIA Pharmaceuticals from $37.00 to $36.00 and set an “outperform” rating for the company in a research report on Thursday, October 8th. William Blair set a $33.00 target price on ACADIA Pharmaceuticals in a research note on Monday, September 28th. Stifel Nicolaus boosted their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a report on Tuesday, July 21st. Finally, Oppenheimer reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, September 23rd. Thirteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.34.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.